Brief: Hemostemix Announces Uc Davis Health Added As A Trial Site For Phase Ii Clinical Trial
25/02/2019 13:34
Hemostemix Inc HEM.V :
* HEMOSTEMIX ANNOUNCES UC DAVIS HEALTH ADDED AS A TRIAL SITE
FOR
PHASE II CLINICAL TRIAL
Source text for Eikon: ID:nGNXwRwXB
Further company coverage: HEM.V
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update